A randomised active-controlled non-inferiority trial of OZURDEX intravitreal implant versus Avastin intravitreal injection in Indigenous patients with or at risk of diabetic macular oedema, at the time of or following cataract surgery. (The OASIS Study)
Latest Information Update: 27 Jul 2022
Price :
$35 *
At a glance
- Drugs Dexamethasone (Primary) ; Bevacizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms OASIS
- 01 Jul 2022 Primary endpoint has been met. (Mean change in Best Corrected Visual Acuity (BCVA), as per Results published in the Clinical and Experimental Ophthalmology
- 01 Jul 2022 Results published in the Clinical and Experimental Ophthalmology
- 05 Nov 2020 Status changed from active, no longer recruiting to completed.